We would love to hear your thoughts about our site and services, please take our survey here.
Interesting thanks. I’ll have to do some more reading!
Imagine 75 years ago. You have a stock with normal price movements and so, according to pure theory, it should be possible to predict which way the crowd will turn. But nobody knows the technical indicators because there’s no tools to do it. So absent that knowledge, would the crowd still turn the same way as they might today?
Charting seems just as much a contributor to price movements these days as it is a measure of it. But then that’s a bit moot if all you really want to know, regardless of why, is which way the herd will turn. That’s the real value of charting imo.
For awareness, from a gov publication on 3/3/24
“ The Chancellor is also confirming that companies will soon be able to apply for a share of the £520 million funding for life sciences manufacturing announced at Autumn Statement, with competitions for large scale investments opening for expressions of interest this summer and medium and smaller sized companies in the autumn. The fund is designed to build resilience for future health emergencies such as influenza pandemics and capitalise on the UK’s world-leading research and development.”
https://www.gov.uk/government/news/360-million-to-boost-british-manufacturing-and-rd
Don’t know if this is something ABDX might consider.
Thanks!
I’ve never understood how price action in and of itself can tell you what’s most likely to happen. For me SP movements are simply a function of supply/demand; what happens based on technical considerations is almost self fulfilling because there will be a weight of enthusiasts, in our case identifying resistance has been broken, who together weight trading to either the demand or supply side based on that technical indication and so drive the price in the direction they all “predicted”. But I’m sure that’s just naive/ignorant!
Let’s see what tomorrow brings
Wyndrum, at the close we had a spread of 8.6 - 9.5, so the mid price was 9.05. This was the case even though dummy sells gave a 9.375 quote.
We only closed at 9.5 because of the uncrossing trade (the auction was interesting BTW with plenty of interest on the buy side). So, unless we get another RNS tomorrow, we will open at 9.05 and not 9.5.
Can I ask, from a charting perspective (which I know nothing about), is it the actual 9.05 close or the 9.5 UT that's relevant?
Thanks in advance
i jotted down who we know we're working with, and who i suspect we are. thought it might help others so posting. ignore as you wish!!
salistick - in sd, tesco, launched in israel, sweden, norway, uk (know)
52 north - neutropenic sepsis - part of idap. going through clinical. in major us initiatives (known)
upfront - lv0 stroke test - part of idap. going through final clinical. ukca hoped for very shortly (known)
condiia bioscience - fuel testing for aviation. (very strongly suspect)
venomaid - test for early diagnosis of correct snakebite (suspect)
folium science - swiftr test to quickly identify salmonella in chickens (pretty relevant given recent news on poland) recently launched in brazil (very strongly suspect)
nib biotec - test for prostate cancer. clinical results to be announced imminently (strongly suspect)
loop diagnostics - septiloop sepsis test (known)
nordixdx - rapid aquaculture test for use in fish farms (suspect)
abingdon simply test range (known)
axxinbio - using our pcrd product in their natflow molecular amplification system. (known)
hormona - ****ne test (known)
ecoflow - environmentally friendly cassette, testing prototypes h2 2024
vjj - vaginal health test (mildly suspect)
protak scientific - enzyme indicators to measure bio-decontamination efficacy (strongly suspect, might even know but cant remember)
zoetis - animal health tests for worlds largest animal health company. certain we have been supplying them for a while.
senzo collaboration
possible continuing collaboration with mhc (previously concepta) for development support and manufacturing.
i don't think this goes even halfway to the 29 projects we know we are working on. as i say, ignore as you wish.
Don't think so Jamrock.
Concepta is MHC - it just changed its name in 2020.
Concepta did sell its manufacturing site in Doncaster to ABDX in 2020, and at the same time agreed to outsource its ongoing development and manufacturing requirements to ABDX. Whether that agreement remains in force (at least for some MHC tests) is questionable I think given that all MHC LFT's are now manufactured in China.
Lets not turn this into a negative board on what was great news today.
True, the contracts in and of themselves will not be game changing, although they may very well expand over time both in terms of sales volumes , new product additions, or both.
The real benefit here, from a retail home testing perspective, is that we can now advertise our CDMO/CRO offering as including relationships with more major retail players in the UK. That cannot hurt when trying to attract new business.
And of course retail consumer home testing is only one of many strings to ABDX bow. Perhaps bigger opportunities lie in supplying national health services with transformative tests to meet unmet need, like 52 North and Upfront, both of which we know have been fast-tracked on election by a panel of regulators and NHS leaders.
And that all ignores the massive plant pathogen, animal health, and environmental sectors we're working on.
It would just be nice if the herd could see through todays RNS and diver deeper into our potential a deeper dive. Then they might understand what most of us on here do.
The Boots brand is established and trusted. No other LFT brand has anywhere near the same level of trust, possibly with the exception of some Covid tests.
And it will no doubt be cheaper than other brands.
Jamrock - if you go into the details of any MHC LFT here, you will see they’re all made in China. Other tests are made by Concepta, possibly in collaboration with ABDX going back to 2020 agreements.
https://www.boots.com/my-health-checked?paging.index=0&paging.size=21&sortBy=mostRelevant&criteria.category=MyHealthChecked
The Chinese tests, at least as far as I can see, are then white labelled by MHC before being sold in Boots.
Alamo - remember the MHC LFT home LFTs are all made in China then white labelled by MHC before being sold in China. 3 parties wanting a bite of the cherry. With this new arrangement there’s only us and boot wanting a slice of the pie, and Boots retain the branding.
If I were Boots I’d expand this new ABDX arrangement over MHC any day of the week.
I do have an ignorant question….
Is it the case that we are simply providing our own Vitamin D and Iron tests to Boots for them to White Label. I’m assuming so given that Yates has confirmed we’re fulfilling material production orders during H2 24. Great if that is the case
Just goes to highlight the very wide broad and diverse mix of revenue opportunities now available to ABDX arising out of general LFT awareness, massive leaps in tech, and the extensive customer base it’s steadily built despite a few years of painful cost control. Well done to the BOD.
Well apart from anything, it gives us a foothold with the largest U.K. pharmacy brand, which is great for us and surely must be attractive to any potential CRO/CDMO partner ultimately looking to commercialise through the retail self test market.
So that’s now Boots, Tesco, and Superdrug we have relations with. Not bad. Not bad at all.
A bit more on VenomAid and their plans to now initiate manufacturing
https://www.venomaid.com/news/venomaid-extends-its-seed-round-to-a-total-of-1-8-m-for-affordable-and-rapid-snakebite-diagnostics